GlassScriptPhysician profile
Alicia Evette Blue
NPI 1245967728
$2,077.16
in general payments reported to CMS, 2019-2025
14 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $198 · 2024: $827 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $461.81 | 2023-2024 | |
| Incyte Corporation | $350.18 | 2024-2025 | Jakafi, Monjuvi, Monjuvi |
| Jazz Pharmaceuticals INC. | $148.66 | 2024 | |
| Servier Pharmaceuticals LLC | $145.80 | 2025 | |
| Syndax Pharmaceuticals, INC. | $128.05 | 2025 | Revuforj |
| Recordati_rare_diseases_inc. | $125.99 | 2025 | Sylvant |
| Kite Pharma, INC. | $123.53 | 2025 | |
| Sobi, INC | $109.35 | 2025 | |
| Glaxosmithkline, LLC. | $109.02 | 2024 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $100.70 | 2023 | |
| Abbvie INC. | $81.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $66.46 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.62 | 2025 | |
| Geron Corporation | $61.47 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Blue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.